WG
CLDX icon

Winton Group’s Celldex Therapeutics CLDX Stock Holding History

Winton Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,322
Closed -$224K – 963
2022
Q2 		$224K Buy
+8,322
New +$242K 0.01% 884
2020
Q4 		– Sell
-24,180
Closed -$359K – 1339
2020
Q3 		$359K Buy
24,180
+4,779
+25% +$56K 0.01% 1197
2020
Q2 		$252K Buy
19,401
+7,374
+61% +$32.7K 0.01% 1317
2020
Q1 		$20K Sell
12,027
-20,000
-62% -$45.2K ﹤0.01% 1371
2019
Q4 		$71K Sell
32,027
-1,634
-5% -$3.79K ﹤0.01% 1498
2019
Q3 		$72K Buy
+33,661
New +$77.9K ﹤0.01% 1479

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Winton Group's CLDX Position: Q3 2022 in Review

Winton Group sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 8,322 shares — an estimated $224K sold.

Winton Group first reported a position in CLDX in Q3 2019 and held it in 6 quarters. The position peaked at $359K in Q3 2020. 158 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

  • Winton Group reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Winton Group sold 8,322 Celldex Therapeutics shares in Q3 2022, an estimated $224K.
  • Winton Group first reported a position in Celldex Therapeutics in Q3 2019 and held it in 6 quarters.
  • Winton Group's Celldex Therapeutics position peaked at $359K in Q3 2020.
  • 158 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on Winton Group's 13F filing for Q3 2022, filed 10 Nov 2022.